Free Trial
NASDAQ:HRMY

Harmony Biosciences (HRMY) Stock Price, News & Analysis

Harmony Biosciences logo
$32.75 +0.51 (+1.58%)
As of 07/8/2025 04:00 PM Eastern

About Harmony Biosciences Stock (NASDAQ:HRMY)

Key Stats

Today's Range
$32.27
$33.11
50-Day Range
$29.47
$35.91
52-Week Range
$26.47
$41.61
Volume
1.06 million shs
Average Volume
633,949 shs
Market Capitalization
$1.88 billion
P/E Ratio
12.50
Dividend Yield
N/A
Price Target
$53.63
Consensus Rating
Buy

Company Overview

Harmony Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

HRMY MarketRank™: 

Harmony Biosciences scored higher than 96% of companies evaluated by MarketBeat, and ranked 51st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Harmony Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Harmony Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harmony Biosciences is 12.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.93.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harmony Biosciences is 12.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.00.

  • Price to Earnings Growth Ratio

    Harmony Biosciences has a PEG Ratio of 0.48. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Harmony Biosciences has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Harmony Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    8.51% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 5.4.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently increased by 9.76%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Harmony Biosciences does not currently pay a dividend.

  • Dividend Growth

    Harmony Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.51% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 5.4.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently increased by 9.76%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Harmony Biosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • Search Interest

    13 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Harmony Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harmony Biosciences' insider trading history.
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HRMY Stock News Headlines

Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Headlines

HRMY Stock Analysis - Frequently Asked Questions

Harmony Biosciences' stock was trading at $34.41 at the beginning of the year. Since then, HRMY stock has decreased by 4.8% and is now trading at $32.75.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its quarterly earnings data on Tuesday, May, 6th. The company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.59 by $0.19. The firm's quarterly revenue was up 19.5% compared to the same quarter last year.
Read the conference call transcript
.

Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Top institutional shareholders of Harmony Biosciences include Gallacher Capital Management LLC (0.02%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, Jeffrey Dierks, Jeffrey M Dayno, John C Jacobs and Sandip Kapadia.
View institutional ownership trends
.

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/06/2025
Today
7/08/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HRMY
CIK
1802665
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

High Price Target
$70.00
Low Price Target
$40.00
Potential Upside/Downside
+64.1%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
12.47
Forward P/E Ratio
13.44
P/E Growth
0.48
Net Income
$145.49 million
Pretax Margin
26.48%

Debt

Sales & Book Value

Annual Sales
$714.73 million
Cash Flow
$2.99 per share
Price / Cash Flow
10.91
Book Value
$11.56 per share
Price / Book
2.83

Miscellaneous

Free Float
43,872,000
Market Cap
$1.88 billion
Optionable
Optionable
Beta
0.83
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:HRMY) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners